Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
doola Launches Agentic LLC Formation: Start a U.S. Company in Minutes Without Leaving Claude or Replit30.4.2026 14:00:00 CEST | Press release
Start a U.S. Company in Minutes Without Leaving Claude or Replit Founders can go from idea to LLC without ever leaving the tool they're building in doola is the first business formation platform to launch a Model Context Protocol (MCP) integration for LLC formation, enabling founders to start an LLC through a conversation directly in Claude or Replit. The flow takes minutes. No new browser. No context switching. Available to US and non-US founders and developers (no US SSN required). doola has helped more than 15,000 founders in 175+ countries start and scale US businesses, backed by $13M in venture capital from Y Combinator, HubSpot Ventures, Nexus Venture Partners, and other top investors. NEW YORK CITY, NY / ACCESS Newswire / April 30, 2026 / doola, the AI Business-in-a-Box™ for global entrepreneurs, today became the first business formation platform to enable native LLC formation within AI agents. With new MCP integrations for Claude and Replit, founders can now form a Wyoming LLC
GoodData is Now GoodData.AI, Reflecting Its AI-First Direction30.4.2026 11:00:00 CEST | Press release
The brand update marks the company's continued shift toward intelligence-driven analytics. SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2026 / GoodData, the AI-native decision intelligence platform, today announced it is rebranding as GoodData.AI. The rebrand reflects a strategic direction GoodData has been building toward for several years. The platform has been developed around a core conviction: that governed, AI-native analytics is the foundation every serious enterprise needs. The semantic layer, context management, open architecture, composability, agentic frameworks, and analytics-as-code introduced over that period were each a step toward that foundation. "GoodData.AI is the name that reflects both where we've been and where the market is going," said Roman Stanek, CEO and Founder of GoodData.AI. "Enterprises need analytics that AI can operate, govern, and trust at scale. That's what we're built for, and we're moving faster than ever to get customers there." That pace is vis
Karbon-X Introduces Corporate Emissions Calculator as Pressure to Quantify Carbon Exposure Accelerates29.4.2026 15:10:00 CEST | Press release
Digital tool enables companies to rapidly assess emissions and take immediate action while preparing for compliance and carbon market participation. CALGARY, AB / ACCESS Newswire / April 29, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today highlighted its Corporate Emissions Calculator, a digital tool designed to help organizations quickly quantify emissions across key operational areas and move from measurement to action. As regulatory frameworks evolve and expectations around emissions disclosure increase, organizations across sectors including energy, manufacturing, aviation, and logistics are facing accelerating pressure to understand and manage their carbon exposure. Many existing solutions remain complex, time-intensive, and reliant on external consultants, creating delays at a time when companies are being pushed to act faster and with greater preci
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses28.4.2026 16:00:00 CEST | Press release
TruMerit 2025 Nurse Migration Report reveals workforce inequities widening across regions. PHILADELPHIA, PA / ACCESS Newswire / April 28, 2026 / TruMerit™ (formerly CGFNS International) today released its 2025 Nurse Migration Report, revealing significant shifts in global nurse migration patterns and widening inequities in nursing workforce distribution across regions with vastly different healthcare needs. The report, which analyzes World Health Organization data and TruMerit's proprietary VisaScreen® application records, shows that international nurse migration flows are increasingly concentrated in regions with stronger healthcare infrastructure, while areas facing severe nursing shortages continue to lose ground in their ability to employ internationally educated nurses. Europe and Southeast Asia see sharp increases in international nurse employment. According to TruMerit's analysis of WHO nursing workforce data, Europe now employs internationally educated nurses at a rate represen
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture28.4.2026 15:00:00 CEST | Press release
Tenstorrent GalaxyTM Blackhole delivers general-purpose AI with native scale-out for winning performance in AI video generation and LLMs - prefill and decode. SANTA CLARA, CA / ACCESS Newswire / April 28, 2026 / Tenstorrent, the AI compute company led by CEO, Jim Keller, announces today general availability of Tenstorrent Galaxy Blackhole deployed at scale, delivering industry-leading general-purpose AI performance. Other solutions require bolting together separate accelerators across fragmented infrastructure. Tenstorrent's Networked AI delivers them natively - compute, memory, and networking unified into a single system optimized for real-world AI workloads. Leading Industry Performance, Affordable Prices General-purpose means leading performance on every workload defining modern AI, not specializing in one. Tenstorrent Galaxy tops video generation, large-context LLM inference in both prefill and decode, and the full range of model architectures shipping today. See it for yourself on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom